0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-408.65%PremiumDec 20, 2024Expiry Date4.02Intrinsic Value100Multiplier30DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.30Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Tiziana Life Sciences Stock Discussion
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its gran...
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
Tiziana Life Sciences (Nasdaq: TLSA) announced its participation in BIO-Europe 2024, scheduled for November 4-6 in Stockholm, Sweden. The company will showcase its recent clinical advancements, particularly focusing on its combination study data involving Ozempic, a GLP-1 agonist, and its lead candidate, intranasal f...
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million
Tiziana Life Sciences announced a registered direct offering of 5,263,158 common shares at $0.95 per share, raising approximately $5 million in gross proceeds. The company also issued an option for investors to acquire an additional 5,263,158 shares at the same price within 75 days, potentially raising another $5 million. The proceeds will fund Phase 2a clinical tr...
Tiziana Life Sciences Announces Positive Results From Ozempic and Nasal Anti-Cd3 Combination Study
Another biotech doing all the hard work and making progress with Alzheimer’s drug treatment trials. imho worth the investment 💵
expected move and now they should announce soon orphan drug status, and then later the results and then later they will be bought out… comment from biotech guy
No comment yet